Discontinued — last reported Q3 '25
GE HealthCare Technologies Redeemable NCI increased by 4.3% to $218.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.3%, from $211.00M to $218.00M. Over 5 years (FY 2020 to FY 2025), Redeemable NCI shows relatively stable performance with a -1.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase indicates higher potential future cash obligations to minority partners, which may impact liquidity and capital allocation flexibility.
This represents equity interests in subsidiaries held by third parties that include redemption features, such as a manda...
Often found in companies with complex joint venture structures or partially owned infrastructure projects; peers report this outside of permanent equity.
redeemable_noncontrolling_interests| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $220.00M | $229.00M | $220.00M | $198.00M | $230.00M | $201.00M | $209.00M | $161.00M | $165.00M | $177.00M | $177.00M | $177.00M | $188.00M | $211.00M | $220.00M | $204.00M | $209.00M | $218.00M |
| QoQ Change | — | +4.1% | -3.9% | -10.0% | +16.2% | -12.6% | +4.0% | -23.0% | +2.5% | +7.3% | +0.0% | +0.0% | +6.2% | +12.2% | +4.3% | -7.3% | +2.5% | +4.3% |
| YoY Change | — | — | — | — | +4.5% | -12.2% | -5.0% | -18.7% | -28.3% | -11.9% | -15.3% | +9.9% | +13.9% | +19.2% | +24.3% | +15.3% | +11.2% | +3.3% |